> Can't help but feel the UK had incredible luck on their side here. Some people might call it incredible luck, while others might say that it was a good decis

> Can't help but feel the UK had incredible luck on their side here. Some people might call it incredible luck, while others might say that it was a good decision made by world leading vaccine experts informed directly by the scientists who created the vaccine. In fact, the BMJ said at the start of January: > The trials of the Oxford-AstraZeneca vaccine did include different spacing between doses, finding that a longer gap (two to three months) led to a greater immune response, but the overall participant numbers were small. In the UK study 59% (1407 of 2377) of the participants who had two standard doses received the second dose between nine and 12 weeks after the first. In the Brazil study only 18.6% (384 of 2063) received a second dose between nine and 12 weeks after the first.3 The combined trial results, published in the Lancet,4 found that vaccine efficacy 14 days after a second dose was higher in the group that had more than six weeks between the two doses (65.4%) than in the group that had less than six weeks between doses (53.4%). So there was knowledge/thoughts when the decision was made that an extended gap could change efficacy. Besides, let’s give the UK’s biomedical community more credit than assuming it was a fluke anyway!